Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications

被引:5435
作者
Gupta, AK
Gupta, M
机构
[1] So Gen Hosp, Crusade Labs Ltd, Glasgow G51 4TF, Lanark, Scotland
[2] Univ Glasgow, Div Biochem & Mol Biol, IBLS, Glasgow G12 8QQ, Lanark, Scotland
关键词
magnetic nanoparticles; MRI; drug delivery; surface modification; hyperthermia; cell labelling; iron oxide;
D O I
10.1016/j.biomaterials.2004.10.012
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Superparamagnetic iron oxide nanoparticles (SPION) with appropriate surface chemistry have been widely used experimentally for numerous in vivo applications such as magnetic resonance imaging contrast enhancement, tissue repair, immunoassay, detoxification of biological fluids, hyperthermia, drug delivery and in cell separation, etc. All these biomedical and bioengineering applications require that these nanoparticles have high magnetization values and size smaller than 100 nm with overall narrow particle size distribution, so that the particles have uniform physical and chemical properties. In addition, these applications need special surface coating of the magnetic particles, which has to be not only non-toxic and biocompatible but also allow a targetable delivery with particle localization in a specific area. To this end, most work in this field has been done in improving the biocompatibility of the materials, but only a few scientific investigations and developments have been carried out in improving the quality of magnetic particles, their size distribution, their shape and surface in addition to characterizing them to get a protocol for the quality control of these particles. Nature of surface coatings and their subsequent geometric arrangement on the nanoparticles determine not only the overall size of the colloid but also play a significant role in biokinetics and biodistribution of nanoparticles in the body. The types of specific coating, or derivatization, for these nanoparticles depend on the end application and should be chosen by keeping a particular application in mind, whether it be aimed at inflammation response or anti-cancer agents. Magnetic nanoparticles can bind to drugs, proteins, enzymes, antibodies, or nucleotides and can be directed to an organ, tissue, or tumour using an external magnetic field or can be heated in alternating magnetic fields for use in hyperthermia. This review discusses the synthetic chemistry, fluid stabilization and surface modification of superpararnagnetic iron oxide nanoparticles, as well as their use for above biomedical applications. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3995 / 4021
页数:27
相关论文
共 255 条
  • [1] Akiyoshi K., 1996, SUPRAMOL SCI, V3, P157, DOI [10.1016/0968-5677(96)00031-4, DOI 10.1016/0968-5677(96)00031-4]
  • [2] [Anonymous], 2003, Rev. Adv. Mater. Sci
  • [3] [Anonymous], 1991, IRON OXIDES LAB
  • [4] Characterization of biophysical and metabolic properties of cells labeled with superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR imaging
    Arbab, AS
    Bashaw, LA
    Miller, BR
    Jordan, EK
    Lewis, BK
    Kalish, H
    Frank, JA
    [J]. RADIOLOGY, 2003, 229 (03) : 838 - 846
  • [5] Synthesis of iron oxide nanoparticles used as MRI contrast agents: A parametric study
    Babes, L
    Denizot, B
    Tanguy, G
    Le Jeune, JJ
    Jallet, P
    [J]. JOURNAL OF COLLOID AND INTERFACE SCIENCE, 1999, 212 (02) : 474 - 482
  • [6] Babincová M, 2001, Z NATURFORSCH C, V56, P909
  • [7] Bagwe RP, 2001, CRIT REV THER DRUG, V18, P77
  • [8] LESSER KNOWN APPLICATIONS OF FERROFLUIDS
    BAILEY, RL
    [J]. JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, 1983, 39 (1-2) : 178 - 182
  • [9] Albumin's role in steroid hormone action and the origins of vertebrates: is albumin an essential protein?
    Baker, ME
    [J]. FEBS LETTERS, 1998, 439 (1-2) : 9 - 12
  • [10] Aggregation-based crystal growth and microstructure development in natural iron oxyhydroxide biomineralization products
    Banfield, JF
    Welch, SA
    Zhang, HZ
    Ebert, TT
    Penn, RL
    [J]. SCIENCE, 2000, 289 (5480) : 751 - 754